BioCryst Pharmaceuticals 第二季度业绩电话会议亮点
· finance.yahoo.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) 公布的第二季度业绩显示，ORLADEYO 营收实现增长，其儿科口服颗粒剂型开始出货，并完成了用于遗传性血管水肿 (HAE) 的关键性 navenibart 试验的入组。总裁兼首席执行官 Charlie Gayer 表示...
BioCryst began shipping ORLADEYO oral pellets for pediatric patients during the week of the call. Gayer said the company had received 47 prescriptions through J...